| Bioactivity | Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities[1]. |
| Invitro | Penpulimab demonstrates better stability and a lower level of host-cell protein residue compared with IgG4 backbone anti-PD-1 antibodies[1].Penpulimab does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) and induces no remarkable IL-6 and IL-8 release by activated macrophages[1].Penpulimab exhibits slower binding off-rate for human PD-1 than Nivolumab (HY-P9903) and Pembrolizumab (HY-P9902)[1].Penpulimab potentiates T cell activation via PD-1/PD-L1 blockade[1]. |
| In Vivo | Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice[2]. Animal Model: |
| Name | Penpulimab |
| CAS | 2350298-92-7 |
| Appearance | Liquid |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Huang Z, et al. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Front Immunol. 2022 Jun 27;13:924542. [2]. Yunlong Shan, et al. Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 2581-2581. |